A Randomized Clinical Hypnosis Pilot Study: Improvements in Self-Reported Pain Impact in Adults with Sickle Cell Disease
Table 5
Baseline clinical data and clinically relevant lab values (n = 31).
Total
Group A (n = 15)
Group B (n = 15)
Clinically relevant lab values
Mean (SD) min–max
Mean (SD)
Mean (SD)
Fetal hemoglobin
12.1 (±7.3) 0.0–27.4
14.2 (±8.4)
10.1 (±5.6)
Red blood cell count
2.7 (±0.5) 1.76–3.82
2.7 (±0.5)
2.6 (±0.6)
Hematocrit
26.7 (±3.5) 19.3–34.2
27.2 (±2.4)
26.1 (±4.3)
TR peak velocity (n = 27)
2.7 (±0.4) 1.70–3.60
2.7 (±0.5)
2.7 (±0.4)
n (%)
n (%)
n (%)
Narcotic analgesics prescribed (baseline)
26 (89.7%)
11 (78.6%)
15 (100%)
Episodes of pain in the past 12 months
Min and max
0–25
0–20
Median
9.5
4
Use of hydroxyurea at baseline
22 (75.9%)
10 (71.4%)
12 (80%)
Patient reported comorbidities
Congestive heart failure
3 (9.7%)
2
1
Chronic lung disease
6 (19.4%)
4
2
Blindness or trouble seeing
4 (12.9%)
4
0
Deafness or difficulty hearing
3 (9.7%)
2
1
Sugar diabetes, mellitus
0
0
0
Asthma
2 (6.5%)
1
1
Ulcer or GI bleeding
1 (3.2%)
0
1
Arthritis or rheumatism
4 (12.9%)
2
2
Sciatic or chronic back pain
6 (19.4%)
3
3
High blood pressure (HTN)
11 (35.5%)
4
7
Angina
2 (6.5%)
2
0
Heart attack or MI
3 (9.7%)
3
0
Stroke
8 (25.8%)
6
2
Kidney disease
3 (9.7%)
3
0
Number of comorbid conditions
1.8 (±1.9)
2.4 (±2.2)
1.3 (±1.3)
Number of medications at baseline
7.4 (±4.1)
8.4 (±3.9)
6.5 (±4.1)
No statistically significant differences were found between groups based on the independent two-sample t-tests. Normal ranges are fetal haemoglobin = 0.0–2.0; red blood cell count = 3.93–5.22; and haematocrit = 34.1–44.9.
